2019
DOI: 10.1016/j.jval.2019.09.383
|View full text |Cite
|
Sign up to set email alerts
|

Pcn187 Budget Impact of Sequential Treatment With Afatinib Followed by Osimertinib Versus First-Line Osimertinib in Non-Small-Cell Lung Cancer Patients With Common Egfr Mutations in the Netherlands

Abstract: Resource use estimates were derived from the literature and analysis of national hospital episode statistics. Diagnosis-related group costs were used (V 2018), supplemented with cost data from Irish tertiary hospitals and the literature. A full incremental analysis was conducted, with incremental cost per quality adjusted life year (QALY) as the outcome. Probabilistic and deterministic sensitivity analyses were conducted. Results: Ipilimumab was excluded due to extended dominance, and nivolumab was dominant of… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles